CD,

I said 

" Why would they want to waste patent protected time and big money setting up required infrastructure when there are others who already do that very well?"

You asked me to expand on this........

Hepalink manufactures products like heparin which are sold all over the world through distribution channels (infrastructure) which are provided by their various big pharma partners. Those distribution channels would take Hepalink considerable time and expense to develop on their own. Time which is very expensive as it would eat into patent protected time during roll out, after Apabetalone is approved.  

Hepalink is very good at what they do and so are their various partners. Unless Apabetalone’s U.S. licensing rights could be had at a bargain price, which I doubt if BETOnMACE is successful, I just don’t think Hepalink seems like a company which would embark on a U.S reinvent the wheel program.  As the largest investor in RVX I’m sure they would rather see Apabetalone’s rights go to a company who could most rapidly and profitably exploit the monetary potential of an approved Apabetalone thereby maximizing the value of Hepalink’s RVX investment either through an outright sale of Resverlogix or through maximizing the generation of royalties to Resverlogix. JMO